Incretin ReviewResearch · Context · Care

Additional dossier

OurView Health Review

When does my next charge process, what happens to an unused prepaid balance, and who handles my clinical follow-up?

Offer observed October 15, 2026

Semaglutide $109/month or $297 prepaid for 3 months; tirzepatide $129/month or $357 prepaid. No advertised membership or shipping fee.

OurView Health lists compounded semaglutide at $109 monthly or $297 prepaid for three months, and compounded tirzepatide at $129 monthly or $357 prepaid for three months. The public offer says prices do not rise with the prescribed dose and that there is no membership or shipping fee. These are advertised plan prices, not evidence of comparative clinical performance. [Source]

This review examines what those prices establish, who provides care and what happens around approval, shipping and cancellation. Public sources were checked October 15, 2026. We did not enroll, authorize payment, receive medication or independently audit clinical outcomes or pharmacy operations.

The three-month figure is an upfront purchase

The semaglutide page explicitly labels its three-month option as $297 payable now, equivalent to $99 per month. The tirzepatide page gives $357 payable now, equivalent to $119 monthly. Each saves $30 against three purchases at the displayed monthly price. The lower monthly equivalent should not be mistaken for a monthly installment. [Tirzepatide offer] [Source]

Both product pages describe thirty-day supplies shipped every thirty days. We did not complete a selected plan or verify its renewal charge, refill processing date, laboratory expense or unused-term refund. The public headline establishes medication pricing, while the final agreement must establish the payment and fulfillment schedule. [Source]

Authorization precedes the clinical decision

The FAQ says checkout authorizes a payment method without immediately collecting payment. A licensed provider reviews the case; payment is finalized after approval and the prescription then goes to a pharmacy. If treatment is not approved, the authorization is released. We did not test a bank hold or measure how quickly a release becomes visible to the cardholder. [Source]

Ask whether a particular assessment, laboratory service or outside prescription has a separate fee, and obtain the answer for the chosen program. A general no-membership statement does not resolve every possible service outside the advertised bundle. The clinical decision should remain separate from a patient’s desire to qualify for the advertised price.

The pharmacy and provider network are named

OurView’s FAQ identifies Boudreaux’s New Drug Store in Louisiana as its 503A compounding-pharmacy partner and Telegra as its provider-network partner. Those names are more specific than the homepage’s pharmacy-direct marketing. We have not independently verified the pharmacy’s current licenses or identified the individual clinician and pharmacy assigned to a particular order. [Source]

The product pages say OurView itself is neither a state-licensed pharmacy nor a manufacturer. The homepage separately says its parent company is a pharmacy. We treat those as the company’s descriptions, not independently verified corporate ownership or proof that there are no additional commercial intermediaries. [Source]

The FAQ lists service in 46 states and Washington, DC, excluding Arkansas, Connecticut, Hawaii and New Jersey. It also says insurance is not accepted. These are current company-published availability and billing statements; individual prescribing eligibility still depends on the licensed provider’s assessment. [Source]

Cancellation and a refund are different events

The refund policy excludes medication returns after dispensing and makes a sale final once payment has been charged and the package handed to the carrier. It allows portal changes or subscription cancellation before products ship. It does not clearly resolve the refund for an approved or dispensed prescription that has not yet reached the carrier. [Source]

The same policy asks patients to report damage or lost deliveries and describes reshipping a lost order after working with the carrier to locate it. Its thirty-day return provision concerns unopened nonprescription goods, not a right to return prescription GLP-1 medication. [Source]

We did not verify a universal advance-renewal deadline or the refund treatment of unused portions of a three-month prepayment. Ask for both before buying the longer option. Save the cancellation confirmation and distinguish stopping the next order from recovering money for one already processed.

A personalized formula still needs evidence for its claims

The tirzepatide page describes glycine in its compounded GLP-1 formulations and uses wellness and personalization language. The semaglutide page also suggests personalization can reduce side effects. We did not identify a product-specific comparative clinical study in the reviewed pages proving those advantages. An added ingredient or personalized label does not establish a better benefit-risk profile. [Source]

FDA explains that compounded GLP-1 drugs are not FDA-approved and do not undergo its premarket review for safety, effectiveness and quality. Evidence about an approved medicine cannot automatically establish equivalent results for a different compounded preparation. [Source]

OurView advertises care coaching, dietitian involvement and around-the-clock support, while the FAQ describes same-day shipping for eligible orders before its stated cutoff. We did not measure response times or delivery. Ask which clinical contact is available and what the service actually commits to after enrollment. [Source]

The marketing-claim guide explains the evidence boundary. The Queen RX review adds a different package structure and shows why a current product menu should be read alongside older general terms.

Source notes

New provider sources checked October 15, 2026. Earlier material retains its original source history. Provider pages document advertised terms. Study summaries identify the scope of our review.

  1. OurView Health: Plan prices and care claimsProvider public information; checked October 15, 2026
  2. OurView Health: Compounded semaglutide offerProvider public information; checked October 15, 2026
  3. OurView Health: Compounded tirzepatide offerProvider public information; checked October 15, 2026
  4. OurView Health: Payment, pharmacy and provider FAQProvider public information; checked October 15, 2026
  5. OurView Health: Return and refund policyProvider public information; checked October 15, 2026
  6. OurView Health: General terms; January 9, 2026Provider public information; checked October 15, 2026
  7. FDA — concerns with unapproved GLP-1 drugsRegulatory and safety context · Checked 2026-10-21

Read the full comparison →